Links Between Inflammatory Bowel Disease and Chronic Obstructive Pulmonary Disease

April L. Raftery, Evelyn Tsantikos, Nicola L. Harris and Margaret L. Hibbs*

Department of Immunology and Pathology, Central Clinical School, Monash University, Melbourne, VIC, Australia

Inflammatory bowel disease (IBD) and chronic obstructive pulmonary disease (COPD) are chronic inflammatory diseases of the gastrointestinal and respiratory tracts, respectively. These mucosal tissues bear commonalities in embryology, structure and physiology. Inherent similarities in immune responses at the two sites, as well as overlapping environmental risk factors, help to explain the increase in prevalence of IBD amongst COPD patients. Over the past decade, a tremendous amount of research has been conducted to define the microbiological makeup of the intestine, known as the intestinal microbiota, and determine its contribution to health and disease. Intestinal microbial dysbiosis is now known to be associated with IBD where it impacts upon intestinal epithelial barrier integrity and leads to augmented immune responses and the perpetuation of chronic inflammation. While much less is known about the lung microbiota, like the intestine, it has its own distinct, diverse microflora, with dysbiosis being reported in respiratory disease settings such as COPD. Recent research has begun to delineate the interaction or crosstalk between the lung and the intestine and how this may influence, or be influenced by, the microbiota. It is now known that microbial products and metabolites can be transferred from the intestine to the lung via the bloodstream, providing a mechanism for communication. While recent studies indicate that intestinal microbiota can influence respiratory health, intestinal dysbiosis in COPD has not yet been described although it is anticipated since factors that lead to dysbiosis are similarly associated with COPD. This review will focus on the gut-lung axis in the context of IBD and COPD, highlighting the role of environmental and genetic factors and the impact of microbial dysbiosis on chronic inflammation in the intestinal tract and lung.

Keywords: inflammatory bowel disease, Crohn's disease metabolites, chronic obstructive pulmonary disease, microbial dysbiosis, gut-lung axis

INTRODUCTION

Inflammatory bowel disease (IBD) and chronic obstructive pulmonary disease (COPD) are chronic inflammatory diseases that affect the gastrointestinal tract and respiratory system, respectively, with both being characterized by recurrent disease cycles that result in tissue damage and worsening of disease symptoms. As mucosal epithelial sites, the gastrointestinal and respiratory tracts share structural similarities which may result in part from common embryonic origin in the primitive foregut (1). Its hypothesized that these structural similarities may account for inherent parallels in the immune responses at these two sites and contribute to the dynamic involvement of the gut-lung axis in inflammation.
CHRONIC INFLAMMATORY DISEASES

Inflammatory Bowel Disease

IBD is an umbrella term that describes chronic relapsing inflammation of the gastrointestinal tract; the major types being Crohn’s disease metabolites (CDM) and ulcerative colitis (UC). CD is characterized by transmural, non-continuous, and non-caseating granulomatous inflammation that can occur at any point along the entirety of the gastrointestinal tract, however, inflammation most commonly manifests in the terminal ileum (2, 3). UC is characterized by continuous inflammation that originates in the rectum and progresses proximally. Unlike CD, the inflammation in UC only affects the mucosa and submucosa and solely manifests in the colon (4, 5). The etiology of IBD has not been fully elucidated, however, a complex interplay of genetic susceptibility, environmental risk factors, inappropriate immune responses directed against the microbiota, intestinal barrier hyperpermeability, and dysbiosis of commensal microbiota of the intestines are thought to contribute to pathogenesis (6) (Figure 1).

Presently there are no curative treatments for IBD. With current management strategies, 10–35% of CD patients will require surgery within the first year of diagnosis, and up to 60% will require surgery within a decade of initial diagnosis (7). For UC, 30% of patients will require a colectomy within 10 years of diagnosis (8). Further research into the mechanisms driving IBD is needed to identify novel therapeutic targets, and a fuller understanding of the role of intestinal microbiota in IBD could provide some valuable insights in pursuit of this.

Chronic Obstructive Pulmonary Disease

COPD is a progressive and largely irreversible disease that is characterized by prolonged inflammation, tissue destruction, and airflow obstruction leading to the reduced functional capacity.
of the lungs. The disease is driven by chronic exaggerated inflammatory responses in the airways and parenchyma of the lungs in response to a noxious insult such as cigarette smoke or environmental pollutants or genetic factors such as alpha-1 antitrypsin deficiency (Figure 1). Airway inflammation drives airway remodeling leading to mucus metaplasia and airway obstruction as well as tissue destruction that results in the enlargement of the alveoli, also known as emphysema. Smoking is a major risk factor for the development of COPD, however, other factors such as chronic asthma, low birth weight, childhood respiratory tract infections, pulmonary tuberculosis, and occupational exposures to dusts have also been associated with COPD (9). The prevalence of COPD has been reported to be as high as 20% in never-smokers suggesting that other risk factors for COPD have been overlooked due to the focus on cigarette smoke (10). COPD is one of the leading causes of mortality worldwide accounting for 3 million deaths annually (11), and much like IBD, there is no curative treatment beyond lung transplantation although this is still up for debate (12).

Linking IBD and COPD

Population based studies have identified an increased prevalence of IBD in patients with COPD, and an increased risk of mortality in patients with both COPD and CD (13–15). Furthermore, the risk of COPD patients developing either CD or UC is increased by 2.72 and 1.83, respectively, compared to healthy controls (13), results that have been confirmed in additional populations (16). Reciprocally, a retrospective study found that CD patients were at increased risk of dying from COPD (17). Additionally, a study in Quebec residents found that asthmatic and COPD patients had increased incidences of CD of 27 and 55%, respectively, compared to the general population in that province (18). There is also evidence that up to 60% of IBD patients have some degree of subclinical lung disease (19). COPD and CD share environmental risks, with cigarette smoke exposure being a major risk factor for both (20). However, this does not explain the increased prevalence of UC amongst COPD patients as cigarette smoke has been proposed to be protective against the development of UC in the general population (21). CD patients without chronic lung disease have reduced pulmonary function that correlates with the presence of sputum lymphocytosis and eosinophilia and inversely with CD activity index (22). This suggests that shared environmental risk factors alone are not sufficient to induce these comorbidities and that alternative mechanisms that link the intestine and lung are responsible.

The epithelium of the respiratory and gastrointestinal systems are derived embryonically from the primitive foregut (1). This shared origin likely underlies the ability of these two mucosal surfaces to act similarly as selective barriers, allowing for the translocation of gases or nutrients, whilst maintaining mutualistic relationships with the microbiota and keeping pathogens at bay. These similarities in function suggest that these tissues may also respond to disease-causing stimuli in the same way, which could account for the increased risk of CD development in COPD patients. Indeed, parallels exist in the immune systems at both mucosal sites and this is mirrored in the immunopathology of IBD and COPD. Both disease settings are characterized by increases in myeloid cells such as neutrophils, eosinophils and macrophages, as well as innate lymphoid cells (ILCs) and unconventional T cells such as γδ T cells, all of which are important in microbial interactions and maintenance of epithelial barriers. While this is beyond the scope of this review, the reader is directed to the following reviews for more information on the pathophysiology and immunopathology of these diseases (23–26). It is well-known that the intestinal epithelium is readily damaged in IBD (27), and increased intestinal permeability has now also been reported in COPD (28, 29). Whilst the association between IBD and COPD has been largely investigated at an epidemiological level, further research is required to elucidate the inflammatory mechanisms that link the intestine and the lung. This review will focus on the mechanisms linking IBD and COPD that pertain to mucosal microbial communities and dysbiosis in disease settings (Figure 1).

MUCOSAL MICROBIAL COMMUNITIES AND DYSBIOSIS IN DISEASE SETTINGS

Healthy Intestinal Microbiota

The gastrointestinal tract is one of the largest surfaces of the body that is constantly in contact with environmental factors. At mucosal sites, such as the intestine, the immune system is primed by interactions with the microbiota and environmental antigens, and a fine homeostatic balance needs to be maintained to ensure quiescence toward harmless microbes whilst being able to promote a proinflammatory response against invading pathogens. The intestine is the most densely colonized surface of the human body with Bacteroidetes and Firmicutes representing the two most abundant bacterial phyla making up approximately 90% of all microorganisms of the gastrointestinal tract (30, 31). A mutualistic relationship exists between the intestinal microbiota and the human host. The intestine provides a nutrient-rich niche for the microbiota to inhabit, whilst the host benefits from the increased digestive capacity that the microbiota provides, from its ability to prime the immune system, and from a reduction in the available niche for potentially pathogenic micro-organisms (32). In addition, the intestinal microbiome contains more than 3.3 million non-redundant genes, 150-fold greater than the human gene complement, and these provide both metabolic and health benefits to the host (33). The microbiota is not stagnant, and its composition can be altered by a variety of factors including diet, infection, inflammation, or antibiotics; and this shift in microbial communities is referred to as dysbiosis. Dysbiosis is often associated with IBD (34, 35) but is also observed in a variety of chronic inflammatory and autoimmune diseases including rheumatoid arthritis, psoriasis, neurodegenerative diseases, diabetes, allergic diseases, and asthma (36–42). At present, essentially nothing is known about the gut microbiota in COPD.

Healthy Lung Microbiota

Historically, due to a reliance on culture-dependent techniques, the lungs were thought to be sterile. With the emergence
of culture-independent techniques utilizing genetic sequencing, pulmonary microbial communities have been found in the healthy lung and characterization of the lung microbiota in the context of respiratory diseases has become possible (43). However, progress in our understanding of the lung microbiota is still limited by factors such as low microbial loads in the lower airways, contamination of samples from the upper airways and oral cavity, and sampling methods that over-represent the upper airways over the lower airways. This is important since the upper and lower airways harbor distinct microbial communities (44). A study comparing the microbial communities of both the oral cavity and the lower airways in healthy non-smokers and smokers identified bacteria that comprised the healthy lung microbiota and showed that lung bacterial communities were not significantly altered by smoking, although differences were apparent in the oral microbiota. Similar to the intestines, the most abundant bacterial phyla present in the lungs were Bacteroidetes and Firmicutes and they did not derive entirely from the mouth as the microbiota of the oral cavity was dominated by Firmicutes, Proteobacteria, and Bacteroidetes (44).

**Dysbiosis of Intestinal Microbiota in IBD**

Dysbiosis has been associated with the development of IBD, although whether this is cause or effect is yet to be elucidated since most research to date has been correlative. Cross-sectional studies are the most common for assessing the microbiota of IBD patients but these only provide a snapshot in time (45). Instituting longitudinal studies could assist in establishing when dysbiosis occurs relative to the onset of intestinal inflammation and how this may change with the course of disease but this would require early and frequent sampling. Furthermore, the microbiome tends to be sequenced from fecal samples and while this is non-invasive for the IBD patient, this method could provide inaccurate measures, especially for CD patients where inflammation is often localized to the ileum or other portions of the gastrointestinal tract. This sampling method can also overlook mucosa-associated microbiota, and due to the variations in microbial composition that are apparent across the gastrointestinal tract, sampling methods need to be carefully considered when formulating studies (46). Nonetheless, the research that has been conducted to date has provided a solid foundation upon which future studies can expand to improve our understanding of dysbiosis in IBD.

Broadly, dysbiosis in IBD patients is associated with shifts promoting an increase in potentially proinflammatory bacteria and a decrease in protective bacteria. In CD patients, intestinal dysbiosis has been characterized by a reduction in diversity of species belonging to the Firmicutes phyla, a change that has been suggested to occur prior to disease onset (34, 47, 48). Furthermore, a specific reduction in relative abundance in *Dialister invitus* and *Faecalibacterium prausnitzii* species of the Firmicutes phylum and *Bifidobacterium adolescentis* of the Actinobacteria phylum, together with an increase in the mucolytic species *Ruminococcus gnavus* and *Ruminococcus torques* of the Firmicutes phylum is observed in CD patients compared to healthy controls (34, 49). The importance of intestinal microbiota in development of IBD is supported by common experimental mouse models, such as nucleotide-binding oligomerization domain-containing protein 2 (NOD2)-deficiency and IL-10-deficiency which ordinarily develop ileitis when maintained under standard housing conditions but display reduced disease penetrance in specific pathogen-free environments (50–53).

Adherent-invasive *Escherichia coli* (AIEC) is an organism that is commonly associated with CD. This bacterium is able to take advantage of gaps in host defense such as impaired bacterial recognition and defective intracellular killing, allowing AIEC to expand (54). AIEC have been found to induce granuloma formation in the inflamed ilea (55), a hallmark pathological feature of CD. These granulomas consist of multinucleated giant cells and epithelioid cells, both phagocytic cells of the macrophage lineage that activate T cells in an antigen-specific manner, that are surrounded by a B cell corona (56). Furthermore, it has been found that AIEC are able to survive and replicate within macrophages without inducing cell death, a process that also promotes increased secretion of proinflammatory tumor necrosis factor-α (TNF-α) (57), which is involved in the pathogenesis of CD.

A study that examined dysbiosis in an inducible model of ileitis using *Toxoplasma gondii* together with high dose indomethacin, found that severe ileitis was associated with a shift in microbial communities from populations dominated by species belonging to the Firmicutes phyla to those largely represented by species belonging to the Proteobacteria phyla (58). This dysbiosis was accompanied by translocation of AIEC and was similar to that observed in CD patients. While these data suggest that inflammation is sufficient to induce dysbiosis, it is also clear that genetic susceptibility plays a role since *T. gondii* induced heightened dysbiosis and AIEC invasion in mice lacking the ileitis susceptibility gene NOD2, while disease was significantly muted in mice lacking the proinflammatory C-C chemokine receptor 2 (CCR2), which are a model of ileitis resistance (58). Furthermore, it has been demonstrated in an alternative genetic knock out model of ileitis susceptibility that dysbiosis precedes the onset of ileitis (59).

Similar to CD, dysbiosis in UC is characterized by a reduction in species belonging to Firmicutes and Bacteroidetes phyla, and a concomitant increase in species belonging to Proteobacteria and Actinobacteria phyla (60). However, at the species level, the dysbiotic signature of UC is distinct from CD. UC patients exhibit a reduction in relative abundance of *Roseburia hominis* and *Faecalibacterium prausnitzii* (35), both butyrate-producing bacteria of the Firmicutes phylum whose abundance is inversely correlated with disease severity (35). A similar mechanism involving the interaction of genetic susceptibility, inflammation and microbial dysbiosis contributes to UC.

**Genetics of IBD and Its Role in Intestinal Dysbiosis**

To date, more than 150 susceptibility genes have been identified for IBD, most of which are involved in the detection and clearance of microbial compounds (61). Three common variants of NOD2 are associated with an increased risk of developing
CD, with a 2–4-fold increase for heterozygous mutations and a 20–40-fold increase for homozygous mutations (62, 63). NOD2 variants are the most common mutations in CD patients of Caucasian descent, being identified in 30% of patients (64). Furthermore, certain variants in NOD2 have been associated with more severe disease phenotypes including early-onset disease, ileitis, and strictures caused by fibrosis (65–67). NOD2 is a cytoplasmic molecule that senses the pattern-associated molecular pattern muramyl dipeptide (MDP) of gram positive and negative bacteria, stimulating the immune response via activation of the transcription factor NF-κB or induction of apoptosis (68). The three common variants found in CD patients all affect NOD2 binding to MDP resulting in loss of function (62). This is thought to cause diminished secretion of antimicrobial peptides, which can lead to dysbiosis and promote a mucosal immune response (69). Functional loss of NOD2 in macrophages may also induce IL-12 and IL-1β expression which leads to the promotion of type 1 immune responses and inflammation (51). Interestingly, not everyone harboring homozygous or compound heterozygous NOD2 variants develop CD (70). Furthermore, NOD2-deficient mice do not spontaneously develop CD-like intestinal inflammation but require a second genetic mutation and specific microbiota (71). This suggests that additional factors, be those microbial, genetic or other environmental factors, are required to promote disease onset in susceptible individuals.

Autophagy-related 16-like protein 1 (ATG16L1) is crucial for normal autophagy function in cells, which is a standard cellular recycling process for protein and organelle turnover that is upregulated during nutrient deprivation or cellular stress signals such as microbial infection. It has been reported that 33.2% of Caucasian CD patients are homozygous for the CD-associated polymorphism rs2241880 (T300A) increasing their risk of developing CD by 2.38-fold (72, 73). This single nucleotide polymorphism is a missense mutation near a caspase cleavage site, making ATG16L1 more sensitive to degradation resulting in diminished autophagy, impaired ability of monocytes to clear invading pathogens and increased production of IL-1β in response to MDP (74). Normal ATG16L1 activity in intestinal epithelial cells (IEC) is important for maintaining the intestinal barrier. The rs2241880 variant in CD patients has been associated with Paneth cell abnormalities, specifically an impaired secretory granule pathway and increased production of proinflammatory mediators (75). Atg16l1-deficiency in IEC has been associated with increased susceptibility to colitis in mice, with increased CD4+ T cells and increased secretion of proinflammatory cytokines such as TNF-α, interferon-γ (IFN-γ) and IL-1β. Thus, diminished autophagy may induce susceptibility through alterations to both immune cell activity and intestinal barrier function.

Changes in NOD2 and ATG16L1, as well as other genes involved in the intestinal epithelial barrier, microbial sensing, and antimicrobial activity in IBD, demonstrate the impact of genetics on the intestinal microbiota. Deficiencies in such genes are a mechanism by which dysbiosis can precede development of IBD and drive intestinal inflammation.

**Dysbiosis in COPD**

**Lung Dysbiosis Is Observed in COPD**

Chronic inflammatory lung diseases such as COPD and asthma have been associated with dysbiosis of the lung microbiota with the outgrowth of pathogenic bacteria. Mucus hypersecretion and lower respiratory tract infections in COPD have been associated with accelerated decline in lung function, indicating that the lung microbiota plays an important role in COPD pathogenesis (76, 77). The microbiota of the bronchial secretions from COPD patients predominately comprises members of the Proteobacteria, Firmicutes, and Actinobacteria phyla (78). Specifically, studies that have assessed the lung microbiota of COPD patients suggest that their bacterial communities differ from those of healthy individuals, with an expansion of *Hemophilus* spp., *Afpia*, *Brevundimonas*, *Curvibacter*, *Moraxella*, *Neisseria* and *Undibacterium* spp. of the Proteobacteria phylum, *Corynebacterium* spp. of the Actinobacteria phylum, *Capnocytophaga* spp. of the Bacteroidetes phylum, and *Leptolyngbya* spp. of the Cyanobacteria phylum, as well as a reduction in microbial community diversity compared to healthy individuals (79–82). Patients with more severe COPD have a less diverse lung microbiota but expansion of more pathogenic microbes (78). Furthermore, during acute exacerbations of COPD, the lung microbiota are more unstable; these exacerbations tend to be associated with reduced species diversity, an increased relative abundance of Proteobacteria mainly due to increased *Moraxella* spp. and a decreased relative abundance of species belonging to the Firmicutes phyla (82, 83). Changes in the core microbiota during acute exacerbations of COPD allow for an expansion of respiratory pathogens including *Acinetobacter* spp. and *Klebsiella* spp. highlighting the important role of the commensal lung microbiota in protecting against the colonization of pathogenic microbes (83). It is worth highlighting that the exact nature of dysbiosis within the lung microbiota that occurs during acute exacerbations of COPD is dependent on the cause of the exacerbation, with specific differences noted between bacterial and eosinophilic exacerbations (characterized by bacterial dysbiosis and elevated sputum eosinophils respectively). The characteristic decrease in species diversity and relative abundance of species belonging to the Firmicutes phyla, alongside an increase in species belonging to the Proteobacteria phyla is more pronounced in bacterial exacerbations (82). Bacterial exacerbations also have a significant decrease in *Streptococcus* spp. and an increase in *Hemophilus* spp. whilst eosinophilic exacerbations exhibit a decrease in the Proteobacteria:Firmicutes ratio (82). Changes in the composition of the lung microbiota are associated with changes in local inflammatory responses, the most significant being the negative correlation between species diversity and CXCL8, which indicates reduced species diversity is associated with an influx in neutrophils (82). Interestingly, in lung transplants, the microbiota influences the immune response with Firmicutes-dominated and Proteobacteria-dominated dysbiosis being proinflammatory, Bacteroidetes-dominated dysbiosis being associated with tissue remodeling, and a balanced microbial community being associated with homeostasis (84). Collectively,
these studies show that respiratory microbial communities can regulate inflammation in the lungs.

**Intestinal Dysbiosis Influences Lung Health**

Recent research has shown that the intestinal microbiota is important in reducing the risk of lung inflammation by supporting mucosal immunity. Studies have shown that depletion of intestinal bacteria through antibiotic treatment, renders mice more susceptible to Pneumonia infection and respiratory inflammation (85, 86). Reciprocally, viral and bacterial respiratory infections are able to drive dysbiosis of the intestinal microbiota demonstrating that respiratory inflammation can influence the intestine (87, 88). In mice lacking an intestinal microbiota, their alveolar macrophages have an altered transcriptome which results in decreased phagocytic activity and bacterial killing (85, 86). Dysbiosis of the intestinal microbiota has been shown to influence the composition of the respiratory microbiota through changes in circulating inflammatory cytokines and translocation of intestinal microbiota to the airways Figure 1, although this has only been demonstrated in severe sepsis models and has not yet been established in COPD. It has been shown that segmented filamentous bacteria (SFB) in the intestines induced Th17 responses and IL-22 production in the lungs and protected against respiratory infection with S. pneumoniae with reduced bacterial burden and lung inflammation (89). In a murine model of sepsis, an increased abundance of gut-specific bacteria in the lungs has been observed, with there being greater similarities between the communities found in the intestines and lungs than in sham mice (90). A meta-analysis of sixteen studies found that infection with H. pylori, which colonizes the human gastric mucosa, was associated with an increased risk of COPD (91). During acute exacerbations of COPD there is a significant decrease in categories of bacteria as defined by operational taxonomic units (OTUs) in the intestinal microbiota (83). Beyond assessing H. pylori infection in COPD patients, and a recent study examining the intestinal microbiota in acute exacerbations of COPD in a small group of patients (83), the intestinal microbiota has not been investigated in COPD. This would be of particular interest since cigarette smoking, which is strongly associated with COPD, has been linked with dysbiosis of fecal microbiota in CD patients, characterized by an increase in the relative abundance of Bacteroides and Prevotella (92).

**Cigarette Smoke Exposure Is a Risk Factor for Both COPD and CD**

Cigarette smoke is the most important risk factor in COPD, with approximately 80% of COPD patients being past or current smokers. Smoking can have prolonged effects on lung inflammation which can persist years after smoking cessation, despite the slowed decline in lung function and better survival (93). In addition, active smoking is also associated with higher mortality rates in COPD patients (94). Both active and passive smoking is the most well recognized environmental risk factor for CD being associated with a 2-fold increased risk of disease (95). It is linked with early onset of disease, as well as more aggressive disease progression with an increase in the occurrence of strictures and fistulas and the increased likelihood of a need for surgical intervention (96–98). Smoking may also influence the locus of inflammation, increasing occurrence in the ileum as opposed to the colon (99). An intervention study investigated the effect of quitting smoking on CD severity and found that patients who stopped for at least a year were less likely to relapse (100). The association between smoking and CD highlights the potential crosstalk between the lungs and intestines, although, the possibility that noxious agents from cigarettes can reach the intestines via the oral route cannot be ignored as an additional CD risk mechanism (101).

Smoking also alters the composition of the intestinal microbiota not only in CD patients but also in smokers without IBD (102). Following smoking cessation, the fecal microbiota is altered in non-IBD individuals with an increased relative abundance of species belonging to Firmicutes and Actinobacteria phyla and a decreased relative abundance of species belonging to Bacteroidetes and Proteobacteria phyla (103). CD patients who smoke exhibit intestinal dysbiosis characterized by a higher Bacteroides:Prevotella ratio compared to non-smokers and healthy smokers (92). Animal studies that examined the impact of smoke exposure on the intestinal microbiota found that smoking increased the relative abundance of Clostridium clostridiforme with a decreased relative abundance of Lactobacillus spp. and Ruminococcus albus of the Firmicutes phylum and Enterobacteriaceae spp. in the cecum compared to control mice (3, 104). Collectively, these studies suggest that dysbiosis of the intestinal microbiota could be another mechanism by which cigarette smoke might increase the risk of CD development.

A study of chronic smoke exposure in mice compared the microbiota across the ileum, cecum, and distal colon finding changes in microbiota (105). The authors described increased activity of Lachnospiraceae spp. in the cecum and colon, which is of particular interest since it has been reported that Lachnospiraceae spp. can promote macrophage recruitment to the colon (106). This study also demonstrated that chronic smoke exposure may impact the intestinal microbiota by altering mucus profiles and the local immune environment. They found that cigarette smoke increased the secretion of the two major ileal mucins, Muc2 and Muc3, and enhanced the cell surface expression of the anti-adhesive Muc4 (105). However, at present it is unclear if these changes are a result of dysbiosis, or of cigarette smoke itself.

Cigarette smoke has been found to increase intestinal barrier permeability in the ileum, but not the colon (107). These changes are associated with intestinal villi atrophy, bacterial translocation and abnormal tight junction proteins, with evidence that they were mediated through NF-κB signaling (107, 108). Cigarette smoke has also been found to alter Paneth cell function in mice through reduced antimicrobial peptide expression and reduced bactericidal capacity, which leaves mice more susceptible to bacterial infection (108). Changes in the ileum, but not the colon, may explain why cigarette smoke increases the risk of developing CD whilst conceivably offering protection against UC (95). Certain susceptibility genes have been associated with epithelial barrier defects in CD patients who smoke. A promoter variant in the gene encoding the aryl hydrocarbon
receptor (AHR) has been linked to increased risk of intestinal hyperpermeability, with cigarette smoking further increasing this risk (109). From an immunological perspective, cigarette smoke induces an IL-17 response with increases in Th17 cells and neutrophils in the lungs and circulation (110). This enhances intestinal Th17 cells and neutrophils, as well as IL-17-producing type 3 innate lymphoid cells (ILC3s), in a manner that is dependent on neutrophil recruitment via IL-17A (110). Thus, in addition to changes in the intestinal epithelial barrier, cigarette smoke can promote intestinal inflammation which is already augmented in individuals who are genetically susceptible to IBD.

Non-bacterial Microbiota in IBD and COPD

To date most studies examining the microbiota in IBD and COPD have focused on bacteria, however, the microbiota also encompasses fungi and viruses. Whilst this review primarily discusses the role of bacterial dysbiosis in IBD and COPD these other microorganisms cannot be ignored. There is evidence to suggest that there are shifts in the intestinal viral and fungal communities during IBD and alterations to pulmonary communities in COPD. However, considerably more research is needed to determine the role of viruses and fungi in the gut-lung axis especially in the context of IBD and COPD.

The Virome and Mycobiome May Contribute to IBD

The intestinal virome is predominately comprised of bacteriophages (111), therefore the interactions between viruses and bacteria during IBD could play a role in dysbiosis and disease pathogenesis (112). The most abundant bacteriophages of the intestine include the Caudovirales order and Microviridae family (113–115) and perhaps not surprisingly, viral dysbiosis in IBD patients is characterized by an increase in Caudovirales species (115, 116). This expansion is associated with reduced bacterial diversity and does not appear to occur secondary to changes in bacterial populations suggesting that the virome may contribute to bacterial dysbiosis and inflammation in IBD (115). However, virome research in IBD is in its infancy and more studies are required to elucidate how changes in intestinal viruses may impact upon other intestinal microorganisms and intestinal inflammation.

A potential role for fungi in IBD pathogenesis was first proposed in 1988 when antibodies directed against Saccharomyces cerevisiae were identified in the blood of CD patients (117). Furthermore, several IBD susceptibility genes are involved in anti-fungal immune responses such as CARD9 and CLEC7A (61). Fungal dysbiosis in IBD has been characterized by an increased Basidiomycota:Ascomycota ratio, decreased proportion of Saccharomyces cerevisiae and an increased proportion of Candida albicans (118). Similar to the virome, further research is needed to understand how changes in the mycobiome during IBD may impact upon other microorganisms and inflammation.

The Virome and Mycobiome in COPD

Similar to the gastrointestinal tract the respiratory tract consists of bacteriophages and eukaryotic viruses (119, 120). COPD patients have a heightened viral load in their lungs with an increased abundance of influenza, cytomegalovirus, and Epstein-Barr virus, the latter of which has been associated with pulmonary fibrosis, a feature of COPD (121–123). More non-targeted approaches are required to define other viruses that may be involved in COPD pathogenesis and dysbiosis.

The most abundant fungi in healthy lungs are of the Davidellaceae family and the genera Cladosporium, Eurotium, Penicillium, and Aspergillus, although many other species including Candida spp. are present as well (124). Compared to healthy individuals, COPD patients have an increased relative abundance of Candida spp. in their lungs (125). Furthermore, the enhanced abundance of Aspergillus, Candida, Phialosimplex, Penicillium, Cladosporium, and Eutypella has been associated with severe exacerbations of COPD (126). Of the chronic pulmonary diseases, COPD is one of the least studied in the context of the mycobiome and more research is required to understand how the mycobiome is altered in COPD patients. Furthermore, the relationship between the non-bacterial microbes of the lung and gut and their role in the gut-lung axis have been poorly considered and are an area for future research.

FACTORS LINKING IBD AND COPD

Dietary-Derived Metabolites Are Protective in IBD and COPD

Certain macro- and micro-nutrients have been inversely associated with the development of CD (127), with dietary fiber being the most extensively researched. Soluble-fiber from fruits and vegetables as opposed to insoluble fiber from whole grains and cereals has shown protection against CD (128). Non-digestible carbohydrates are fermented by saccharolytic bacteria in the gastrointestinal tract into metabolites known as short-chain fatty acids (SCFA), which include acetate, propionate, and butyrate. Acetate and propionate are produced by Bacteroidetes and butyrate by Firmicutes and these SCFA can be immunomodulatory by preventing the transcription of proinflammatory mediators. Butyrate in particular is an energy source for IEC thereby promoting intestinal barrier integrity (129), and thus it is not surprising that a decrease in butyrate-producing bacteria is a characteristic of intestinal dysbiosis in IBD (35). Experimental models of IBD have shown that dietary SCFA reduce inflammation, specifically via decreases in proinflammatory mediators such as TNF-α and nitric oxide synthase which correlates with increased concentrations of butyrate and propionate in the luminal contents of the intestines (130, 131). However, the efficacy of SCFA in IBD patients has been brought into question due to the reduced responsiveness of their peripheral blood mononuclear cells to n-butyrate following toll-like receptor-2 (TLR-2) activation (132). Furthermore, for UC patients, butyrate enemas have shown no clinical benefit (133). This could be due to the finding that monocarboxylate transporter 1, which is responsible for the uptake of butyrate in the intestine, is downregulated in response to proinflammatory cytokines and its expression.
is reduced in the inflamed mucosa of IBD patients and in a rat model of colitis (134). Interestingly, studies examining the fecal contents of CD patients found that disease activity or localization was not affected by SCFA concentration, although CD disease activity was inversely correlated to levels of the medium-chain fatty acid hexanoate (135, 136). Contradictory to these studies, a clinical trial examining the effects of soluble fiber supplements showed that high fiber could reduce disease activity index in CD patients (137). Discrepancies in research may reflect the heterogeneity of CD as well as differences in diets, and thus, further research is required to elucidate the effects of the different components of diet on intestinal inflammation.

It is now known that SCFA can have immunomodulatory effects beyond the intestines where they are produced, promoting anti-inflammatory responses elsewhere in the body. Dysregulated SCFA production and absorption has been implicated in a variety of neurological, metabolic, allergic, and autoimmune diseases (138–141). In the context of the lungs, increased dietary fiber intake is associated with improved lung function in the general population and a reduced risk of developing COPD (142, 143). Increased intake of vegetables, which are high in soluble fiber, is associated with improved COPD symptoms such as breathlessness, as well as reduced risk of developing COPD (144). Similar to vegetables, high dietary fruit intake has also been associated with improved COPD outcomes and reduced incidence of COPD (145–148). Despite this correlation between increased dietary fiber intake and protection against COPD, there have been few reports on the efficacy of SCFAs specifically in COPD pathogenesis highlighting that this is an understudied area worthy of further research. High fiber diet-producing SCFAs have been shown to be immunomodulatory in asthma responses by enhancing the production of dendritic cells that seed the lungs but have an impaired ability to promote pathogenic type 2 immune responses (149). A more recent study building on these findings has shown that high fiber diets protect against influenza by enhancing the generation of Ly6c− patrolling monocytes from progenitors. This led to an increase in alternatively activated macrophages in lungs and restrained neutrophil recruitment while simultaneously enhancing influenza-specific CD8 T cells responses (150). Similar mechanisms may be associated with the protection created by high fiber diets in COPD where neutrophils play a key pathogenic role in the inflamed lungs. COPD patients exhibit poor responses to influenza vaccination (151, 152) and thus, diet modulation may be a mechanism to improve vaccination outcomes for this susceptible population. In all, modulation of intestinal microbiota with high fiber diets might be beneficial to IBD and COPD patients (Figure 1), however, further research is required to determine how efficacious this strategy would be.

**Dietary Fat Can Alter the Gut Microbiota and Influence Disease**

Foods high in saturated fat or “Western” diets have been associated with a variety of autoimmune and chronic inflammatory disease including IBD and COPD (142, 153, 154). A “Western” diet can influence the composition of the intestinal microbiota, promote intestinal barrier permeability, and enhance inflammation (155–157). Generally, fat intake is able to induce proinflammatory responses through the increase in cytokines, including TNF-α and IL-6, and neutrophils in circulation, all of which play a pathogenic role in IBD and COPD (155, 158). Intestinal dysbiosis induced by fat intake is characterized by an increased Firmicutes:Bacteroidetes ratio and the promotion of endotoxemia, which induces intestinal barrier hyperpermeability (156, 157, 159). In CD patients, the changes induced by a high fat diet that contribute to dysbiosis include increased intestinal barrier permeability, reduced mucus layer thickness and increased NOD2, TLR5, and carinoembryonic antigen-related cell adhesion molecule 6 (CEABAC6) expression, all of which allow for AIEC colonization (49, 160). Generally, a high fat diet tends to be associated with a low fiber diet, and thus, a “Western” diet may contribute to IBD and COPD pathogenesis not only through direct proinflammatory mechanisms but also indirectly through a reduction in the anti-inflammatory benefits of SCFAs.

**Vitamin D Alters the Microbiota and May Have Therapeutic Benefits in CD and COPD**

Vitamin D deficiency commonly occurs in IBD patients and has been associated with diagnosis and the need for surgical intervention (161). In keeping with this, colitis-prone IL-10-deficient mice exhibit a decline in vitamin D receptor (VDR) expression that correlates with colitis symptoms (162). In addition, mouse models unable to produce the active form of vitamin D, 1,25-dihydroxycholecalciferol [1,25(OH)2D3], or lacking the VDR are more susceptible to DSS-induced colitis and this is associated with intestinal dysbiosis characterized by an increase in species of the Proteobacteria phylum and a decrease in species of the Firmicutes phylum (163, 164). VDR signaling regulates numerous antimicrobial processes including the expression of β-defensins, cathelicidin antimicrobial peptides, and ATG16L1 (162). In IBD patients, reduced ATG16L1 expression due to deficiency in VDR signaling promotes an overrepresentation of intestinal Bacteroides and a decrease in butyrate-producing bacteria (162). Interestingly, treating human IEC with butyrate upregulates VDR expression, a phenomenon that also translated to IL-10-deficient mice that were given butyrate, suggesting a close link between the microbiota and vitamin D signaling (162). Vitamin D supplementation in CD patients results in an increase in Firmicutes species correcting some of the dysbiosis that occurs in CD (165). In COPD patients, increased vitamin D intake is positively associated with improved lung function, and like IBD, vitamin D deficiency is associated with COPD (166, 167). This could relate to the effect of vitamin D on the intestinal microbiota. Additionally, vitamin D plays a role in macrophage activation and shaping the lung microbiota promoting reduced bacterial richness (168, 169). VDR-deficient mice exhibit increased inflammation in the...
lungs with up-regulation of matrix metalloproteinase-2 (MMP-2), MMP-9, and MMP-12, the development of emphysema and a decline in lung function mimicking COPD in humans (170). Studies where mice are fed vitamin D have shown that vitamin D reduces the abundance of respiratory pathobionts, such as *Pseudomonas*, and increases the secretion of murine β-defensin-2 in the lungs (171). To date, very little has been done examining the impact of vitamin D supplementation on the lung microbiota. One study in cystic fibrosis patients found that the sputum of vitamin D insufficient patients was enriched for *Bacteroides* and there was a significant difference between the lung microbiota of these patients and those who were vitamin D sufficient (172). It is clear that the immunomodulatory and microbiota-regulating effects of vitamin D can strongly influence inflammation in both the intestine and the lungs. Given that vitamin D deficiency is associated with both IBD and COPD, vitamin D supplementation should be trialed more extensively in these patient cohorts, specifically in patients with comorbid IBD and COPD.

**THERAPEUTIC TARGETING OF THE INTESTINAL MICROBIOTA**

**Antibiotics for IBD: the Yin and Yang**

Early-life antibiotic treatment has been associated with early onset CD via enhanced pathogenicity of helper T cells (173). This link is particularly strong in children who have received multiple doses of antibiotics or antibiotics during their first year of life (174, 175). Antibiotics cause dysbiosis of intestinal microbiota and a reduction in bacterial diversity, and this may be a potential mechanism by which antibiotic therapy in early life could result in the development of CD in genetically susceptible individuals (176). Furthermore, short-term antibiotic treatment may have prolonged effects, up to at least 2 years post-therapy (177). In infancy, the intestinal microbiota between individuals can be highly variable, before converging to more similar phyla in adulthood (178). This may in part explain the profound impact of antibiotic treatment on the microbiota in early childhood.

While antibiotics given in early life may promote CD, they have been used to treat CD with varying levels of success, and this appears to be dependent on disease location and severity as well as the type of antibiotic (179). Differences in populations of commensal bacteria between the ileum and colon most likely contribute to the lack of response of ileitis patients to a variety of antibiotics (179, 180). Patients who had undergone ileal resection and were treated with metronidazole, an antibiotic that is usually ineffective in patients with ileitis (180), exhibited a delay in symptomatic recurrence (181). A systematic review of antibiotic therapy in CD patients found that antibiotics likely have a modest effect that may not be clinically relevant (182). Furthermore, to maintain antibiotic treatment efficacy and prevent relapse, long-term treatment is required, as with all therapies for CD (183, 184). All in all, antibiotics in early life may increase the risk of CD development in susceptible individuals but may be beneficial as a therapeutic in established disease.

Unlike CD, antibiotic exposure is not associated with an increased risk of developing UC (173) and indeed antibiotics are effective as an adjunctive to conventional therapies, including corticosteroids and 5-aminosalicylic acid (185). This emphasizes the pathogenic role that bacterial dysbiosis plays in UC and suggests that more therapeutics targeting both inflammation and dysbiosis could benefit a large proportion of UC patients.

**Antibiotics for COPD Are Used to Manage Disease Exacerbations**

Persistent and recurrent infections contribute to the progression of COPD through the induction of further chronic inflammation. Antibiotics are commonly used to treat acute exacerbations of COPD, however, the efficacy of antibiotic treatment in mild to moderate exacerbations is still in debate (186, 187). Treatment of COPD patients with antibiotics enhances respiratory microbiota diversity, decreases the relative abundance of Proteobacteria species and increases the relative abundance of Firmicutes species. These changes somewhat correct the dysbiosis associated with COPD, an effect that is maintained post-therapy (80, 82). Contrary to antibiotic therapy, corticosteroids are associated with a decrease in species diversity and an increase of Proteobacteria over Firmicutes corresponding to an increase in *Hemophilus* spp. and *Moraxella* spp. and a decrease in *Streptococcus* spp. changes that are associated with COPD pathogenesis (82). The differing effects of antibiotics and corticosteroids on the lung microbiota suggest that antibiotics are able to partially restore lung microbial communities whilst corticosteroids may further promote dysbiosis. Macrolides are the most commonly prescribed antibiotics for COPD due to both anti-inflammatory and immunomodulatory effects, however, the mechanisms by which macrolides exert these effects have not been elucidated (188). Relatively few COPD patients are treated with antibiotics long-term (189), however, the few studies that have been conducted suggest that prophylactic antibiotic treatment can reduce exacerbations in COPD patients (190). Nonetheless, further studies are required to understand whether long-term antibiotics are efficacious and the impact they have on the lung and intestinal microbiota.

**Fecal Microbiota Transplants, a Possible Treatment Strategy**

Fecal microbial transplants are effective in the treatment of *Clostridium difficile* infection, an intestinal disease that is linked to intestinal bacterial dysbiosis (191). Success is associated with an expansion in bacterial diversity including increases in *Bacteroidetes*, Firmicutes and other butyrate-producing bacteria and a decrease in Proteobacteria (192). In patients with UC, fecal microbial transplants have some initial benefit by promoting a change in colonic microbiota at the phylum level with a decrease in the relative abundance of Proteobacteria species and an increase in *Bacteroidetes* species. While this partially corrects the dysbiotic changes that are associated with UC, these changes were not prolonged and did not translate to a vast clinical improvement (193). Another study where patients were treated with antibiotics prior to fecal microbial transplant had better clinical outcomes resulting in remission (194). Patients who respond to fecal microbial transplants have been characterized
by distinct microbial profiles compared to non-responders. Alterations in microbiota in responders is characterized by an increase in bacterial diversity as well as a shift in composition toward that of the donor feces (195, 196). Lack of response is associated with the presence of Faecalibacterium spp. and Sutterella spp. suggesting that patients should be screened prior to treatment (196). Studies examining the efficacy of fecal microbial transplants for UC have yielded variable results, which could be due to a lack of consistency in methodology as well as the heterogeneous nature of UC and more work is required to establish if this could be an efficacious treatment strategy.

In the context of CD, there has been far less research into the efficacy of fecal microbial transplants and at present it is not clear if this could be a management strategy for CD patients (197, 198). With respect to COPD, no fecal or respiratory microbiota transplant studies have been conducted and thus it is not yet known if these strategies could be a viable option for this disease.

CONCLUSION

Microbial dysbiosis has a pivotal role in the development of IBD and COPD impacting on the intestinal and respiratory epithelial barriers and promoting damaging immune responses. Circulating microbial products and their metabolites are altered during dysbiosis and likely represent a significant component of the gut-lung axis. Shifts in these factors, where they may be produced at one site and act at another, provides a mechanism for organ crosstalk in disease and the comorbid presentation of IBD and COPD. Currently there are no curative treatments for either disease. However, elucidating the mechanisms by which the intestinal and respiratory microbiota drive inflammation and promote changes in mucosal epithelial barriers could provide new insights into disease pathogenesis and help to improve current treatment strategies and identify novel therapeutic targets. These may include approaches that target the microbiota such as diet, antibiotics or fecal microbiota transplants which may be able to modulate inflammation in the intestines and lungs. Most microbiota studies have focused on either IBD or COPD and have largely ignored patients with both diseases. Additionally, there are no reports of gut microbiota alterations in COPD, with published studies focused solely on the lung metagenome. Future studies into patients that harbor COPD, as well as patients with both mucosal inflammatory diseases will provide a more complete understanding of the microbiota in the gut-lung axis in health and disease. Furthermore, increasing awareness and understanding of the links between IBD and COPD will improve clinical management and more timely detection of comorbid disease in affected patients.

AUTHOR CONTRIBUTIONS

AR, NH, and MH conceived and planned the review. AR wrote the first draft of the manuscript. ET, NH, and MH provided editorial comment. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by grant funding from the National Health and Medical Research Council of Australia (APP1147267 to MH, APP1141208 to MH, and ET and APP1140313 to NH). AR was supported by a scholarship from the Australia Government administered by Monash University. NH is supported by a National Health and Medical Research Council (NHMRC) of Australia SRF-B fellowship.

REFERENCES

1. Girosi D, Bellodi S, Sabatini F, Rossi GA. The lung and the gut: common origins, close links. Paediatr Respir Rev (2006) 7:S23–9. doi: 10.1016/j.prrv.2006.04.192
2. Gajendran M, Loganathan P, Catinella AP, Hashash JG. A comprehensive review and update on Crohn’s disease. Dis Mon. (2018) 64:20–57. doi: 10.1016/j.dismon.2017.07.001
3. Savin Z, Kivity S, Yonath H, Yehuda S. Smoking and the intestinal microbiome. Arch Microbiol. (2018) 200:677–84. doi: 10.1007/s00203-018-1506-2
4. Head KA, Jurenka JS. Inflammatory bowel disease part I: ulcerative colitis—pathophysiology and conventional and alternative treatment options. Altern Med Rev. (2003) 8:247–83.
5. Khor B, Agnès G, Ramnik JX. Genetics and pathogenesis of inflammatory bowel disease. Nature. (2011) 474:307–17. doi: 10.1038/nature10209
6. McGovern DPP, Jones MR, Taylor KD, Marcianie K, Yan X, Dubinsky M, et al. Fucosyltransferase 2 (FUT2) non-secretor status is associated with Crohn’s disease. Hum Mol Genet. (2010) 19:3468–76. doi: 10.1093/hmg/ddg248
7. Bernstein CN, Loftus EV, Ng SC, Lakatos PL, Moun M. Hospitalisations and surgery in Crohn’s disease. Gut. (2012) 61:622–9. doi: 10.1136/gutjnl-2011-301397
8. Cottone M, Scimeca D, Mocciaro F, Civitavecchia G, Perricone G, Orlando A. Clinical course of ulcerative colitis. Dig Liver Dis. (2008) 40:S247–52. doi: 10.1016/S1590-8658(08)60533-2
9. Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. (2016) 138:16–27. doi: 10.1016/j.jaci.2016.05.011
10. Lamprécht B, McBurnie MA, Vollmer WM, Gudmundsson G, Welte T, Nizankowska-Mogilnicka E, et al. COPD in never smokers: results from the population-based burden of obstructive lung disease study. Chest. (2011) 139:752–63. doi: 10.1378/chest.10-1253
11. Lopez A. Measuring the global burden of disease. N Engl J Med. (2013) 369:448–57. doi: 10.1056/NEJMr1201534
12. Siddiqui FM, Diamond JM. Lung transplantation for chronic obstructive pulmonary disease: past, present, and future directions. Curr Opin Pulm Med. (2018) 24:199–204. doi: 10.1097/MCP.0000000000000452
13. Ekbom A, Brandt L, Granath F, Löfdahl C-G, Egesten A. Increased risk of both ulcerative colitis and crohn’s disease in a population suffering from COPD. Lung. (2008) 186:167–72. doi: 10.1007/s00408-008-9080-z
14. Durićova D, Pedersen N, Ekbom A, Munkholm P, Jess T. Overall and cause-specific mortality in Crohn’s disease: a meta-analysis of population-based studies. Inflamm Bowel Dis. (2010) 16:347–53. doi: 10.1002/ibd.21007
15. Vutucović M, Bitton A, Ernst P, Keouzh A, Suissa S, Brassard P. Inflammatory bowel disease and risk of mortality in COPD. *Eur Respir J*. (2016) 47:1357–64. doi: 10.1183/13993003.01945-2015

16. Lee J, Im JP, Han K, Park S, Soh H, Choi K, et al. Risk of inflammatory bowel disease in patients with chronic obstructive pulmonary disease: a nationwide, population-based study. *World J Gastroenterol*. (2019) 25:6354–64. doi: 10.3748/wjg.v25.i42.6354

17. Jess T, Loftus EV, Harmsen WS, Zinsmeister AR, Tremaine WJ, Melton LJ, et al. Survival and cause specific mortality in patients with inflammatory bowel disease: a long term outcome study in Olmsted County, Minnesota, 1940-2004. *Gut*. (2006) 55:1248–54. doi: 10.1136/gut.2005.079350

18. Brassard P, Vutucović M, Ernst P, Patenaude V, Sewitch M, Suissa S, et al. Increased incidence of inflammatory bowel disease in Quebec residents with airway diseases. *Eur Respir J*. (2015) 45:962–8. doi: 10.1183/09031936.00079414

19. Vutucović M, Brassard P, Bitton A. Inflammatory bowel disease and airway diseases. *World J Gastroenterol*. (2016) 22:7735–41. doi: 10.3748/wjg.v22.i34.7735

20. Keely S, Talley NJ, Hansbro PM. Pulmonary-intestinal cross-talk in mucosal inflammatory disease. *Mucosal Immunol*. (2011) 5:7–18. doi: 10.1038/mi.2011.55

21. Van Der Heide KF, Dijkstra AA, Weersma MJR, Van Der Slot JG, Faber HK, et al. Effects of active and passive smoking on disease course of Crohn’s disease and ulcerative colitis. *Inflamm Bowel Dis*. (2009) 15:1199–207. doi: 10.1002/ibd.20884

22. LiXQ, Yi YB, Wang SX, Zhang CQ, Lu DG. Alterations of pulmonary function in patients with inflammatory bowel disease. *Ann Thorac Med*. (2016) 11:249–53. doi: 10.4103/1817-1737.191877

23. Caramori G, Casolaro P, Barczyk A, Durham AL, Di Stefano A, Adcock I. COPD immunopathology. *Semin Immunopathol*. (2016) 38:497–515. doi: 10.1007/s00281-016-0561-5

24. Pickard JM, Zeng MY, Caruso R, Núñez G. Gut microbiota: Role in pathogen infection and airway diseases. *World J Gastroenterol*. (2016) 22:2689–95. doi: 10.3748/wjg.v22.i12.2689

25. Gill S, Pop M, Deboy R, Eckburg P, Turnbaugh P, Samuel B, et al. Metagenomic analysis of the human distal gut microbiome. *Nature*. (2006) 444:1022–6. doi: 10.1038/nature05424

26. Maynard CL, Elson CO, Hatton RD, Weaver CT. Reciprocal interactions of the intestinal microbiota and immune system. *Nature*. (2012) 492:231–40. doi: 10.1038/nature11551

27. Martini E, Krug SM, Siegmund B, Neurath MF, Becker C. Mend your fences: the epithelial barrier and its relationship with mucosal immunity in inflammatory bowel disease. *Cell Mol Gastroenterol Hepatol*. (2017) 4:33–46. doi: 10.1016/j.immuni.2019.03.017

28. Maharshak N, Packey CD, Ellermann M, Manick S, Siddle JP, Huh EY, et al. A decrease of the butyrate-producing species *Faecalibacterium prausnitzii* defines dysbiosis in patients with ulcerative colitis. *Gut*. (2014) 63:1275–83. doi: 10.1136/gutjnl-2013-304833

29. Kaufman A, Rosenstrech DL. Mast cell heterogeneity in chronic idiopathic urticaria. *Ann Allergy*. (1990) 65:367–73.

30. Collins SM, Surette M, Bercik P. The interplay between the intestinal microbiota and the brain. *Nat Rev Microbiol*. (2012) 10:735. doi: 10.1038/nrmicro2876

31. Abrahamsson TR, Jakobsson HE, Andersson AF, Björkståen B, Engrand L, Jemmeln MC. Low gut microbiota diversity in early infancy precedes asthma at school age. *Clin Exp Allergy*. (2014) 44:842–50. doi: 10.1111/cea.12253

32. Hua X, Goedert JJ, Pu A, Yu G, Shi J. Allergy associations with the adult fecal microbiota: analysis of the american gut project. *EBioMedicine*. (2016) 3:172–9. doi: 10.1016/j.ebiom.2015.11.038

33. Sprooten RTM, Lenaerts K, Braeken DCW, Grimbergen I, Rutten EP, et al. Increased incidence of inflammatory bowel disease in adults: results from a large population based study. *Eur Respir J*. (2017) 49:1560–70. doi: 10.1183/13993003.009783

34. Maeda Y, Kurakawa T, Unemoto E, Motooka D, Ito Y, Gotoh K, et al. Dysbiosis contributes to arthritis development via activation of autoreactive T cells in the intestine. *Arthritis Rheumatol*. (2016) 68:2646–61. doi: 10.1002/art.39783

35. Li X, Watanabe K, Kimura I. Gut microbiota dysbiosis drives and implies novel therapeutic strategies for diabetes mellitus and related metabolic diseases. *Front Immunol*. (2017) 8:1882. doi: 10.3389/fimmu.2017.018820

36. Hidalgo-Cabranes C, Gómez J, Delgado S, Requena-López S, Queiro-Silva R, Margolles A, et al. Gut microbiota dysbiosis in a cohort of patients with psoriasis. *Br J Dermatol*. (2019) 181:1287–95. doi: 10.1111/bjd.17931

37. Beck JM, Young VB, Huffnagle GB. The microbiome of the lung. *Tranls Res*. (2012) 160:258–66. doi: 10.1016/j.trsl.2012.02.005

38. Morris A, Beck J, Schloss P, Campbell T, Crothers K, Curtis J, et al. Comparison of the respiratory microbiome in healthy nonsmokers and smokers. *Am J Respir Crit Care Med*. (2013) 187:1067–75. doi: 10.1164/rccm.201210-1911OC

39. Prosberg M, Bendsen F, Vind I, Petersen AM, Glud LL. The association between the gut microbiota and the inflammatory bowel disease activity: a systematic review and meta-analysis. *Scand J Gastroenterol*. (2016) 51:1407–15. doi: 10.1080/03005378.2016.1216587

40. Zhang S, Cao X, Huang H. Sampling strategies for three-dimensional spatial community structure in IBD microbiota research. *Front Cell Infect Microbiol*. (2017) 7:51. doi: 10.3389/fcimb.2017.00051

41. Manichanh C, Rigottier-Gois L, Bonnaud E, Gloux K, Pelletier E, Frangeul L, et al. Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach. *Gut*. (2006) 55:205–11. doi: 10.1136/gut.2005.073817

42. Kang ES, Denman SS, Morrison SM, Yu SZ, Dore SJ, Leclerc SM, et al. Dysbiosis of fecal microbiota in Crohn’s disease patients as revealed by a custom phylogenetic microarray. *Inflamm Bowel Dis*. (2010) 16:2034–42. doi: 10.1002/ibd.21319

43. Martínez-Medina LM, Aldeguer LX, Gonzalez-Huix LF, Acero LD, Garcia-Gil LJ. Abnormal microbiota composition in the ileocecal mucosa of Crohn’s disease patients as revealed by polymerase chain reaction-denaturing gradient gel electrophoresis. *Inflamm Bowel Dis*. (2012) 18:1136–45. doi: 10.1097/MIB.0b013e31820ab181

44. Maharshak N, Packey CD, Ellermann M, Manick S, Siddle JP, Huh EY, et al. Altered enteric microbiota ecology in inflammatory bowel disease patients during development and progression of intestinal inflammation. *Gut Microbes*. (2013) 4:316–24. doi: 10.4161/gmic.25486

45. Al Nabhani Z, Lepage P, Mauny P, Montcuquet N, Roy M, Le Roux K, et al. Nod2 deficiency leads to a specific and transmissible mucosa-associated bacterial dysbiosis which is independent of the mucosal barrier defect. *J Crohns Colitis*. (2016) 10:142–36. doi: 10.1093/ecco-jcc/jjw095

46. Blatchford I, Hansen R, El-Omar EM, Hold GL. IBD-what role do Proteobacteria play? *Nat Rev Gastroenterol Hepatol*. (2012) 9:219–30. doi: 10.1038/nrgastro.2012.14
55. Meconi S, Vercellone A, Levilhan F, Payré B, Al Saati T, Capilla F, et al. Adherent-invasive Escherichia coli isolated from Crohn’s disease patients induce granulomas in vitro. Cell Microbiol. (2007) 9:1252–61. doi: 10.1111/j.1462-5822.2006.00868.x

56. Ianssen CEI, Rose CD, De Hertogh G, Martin TM, Bader Meunier B, et al. Morphologic and immunohistochemical characterization of granulomas in the nucleotide oligomerization domain 2–related disorders Blau syndrome and Crohn disease. J Allergy Clin Immunol. (2012) 129:1076–84. doi: 10.1016/j.jaci.2012.02.004

57. Glasser A, Boudeau J, Barnich N, Perruchot M, Colombel J, Darfeuil-Michaud A. Adherent invasive Escherichia coli strains from patients with crohn’s disease survive and replicate within macrophages without inducing host cell death. Infect Immun. (2001) 69:5529–37. doi: 10.1128/IAI.69.9.5529-5537.2001

58. Craven M, Egan CE, Dowd SE, McDonough SP, Dogan B, Denkers EY, et al. Inflammation drives dysbiosis and bacterial invasion in murine models of ileal Crohn’s disease (inflammation drives ileal dysbiosis). PLoS ONE. (2012) 7:e41594. doi: 10.1371/journal.pone.0041594

59. Dobranowski PA, Tang C, Sauvé JP, Menzies SC, Sly LM. Compositional changes to the ileal microbiome precede the onset of spontaneous ileitis in SHIP deficient mice. Gut Microbes. (2019) 10:578–98. doi: 10.1080/19490976.2018.1586077

60. Frank DN, St. Amand AL, Feldman RA, Boedecker EC, Harpaz N, Pace NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U.S.A. (2007) 104:13780–5. doi: 10.1073/pnas.0706625104

61. Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, et al. Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. (2012) 491:119–24. doi: 10.1038/nature11582

62. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cézard JP, Belaiche J, et al. NOD2/CARD15 genotype and common Crohn’s disease. Nature. (2001) 411:599–603. doi: 10.1038/35079107

63. Ogura Y, Lala S, Xin W, Smith E, Dowds TA, Chen FJ, et al. Expression of NOD2 in paneth cells: a possible link to Crohn’s ileitis. Gut. (2003) 52:159–71. doi: 10.1136/gut.52.11.1591

64. Yazdanyar S, Nordestgaard BG. NOD2/CARD15 genotype and common gastrointestinal diseases in 43,600 individuals. J Intern Med. (2010) 267:228–36. doi: 10.1111/j.1365-2969.2009.02137.x

65. Büning C, Genschel J, Bühner S, Krüger S, Kling K, Dignass A, et al. NOD2/CARD15, ATG16L1 and IL23R gene polymorphisms and in vitro patients induce granulomas. Gut. (2007) 69:5529–37. doi: 10.1136/gut.2007.098025

66. Seiderer J, Schnitzler F, Brand S, Staudinger T, Pfennig S, Herrmann K, et al. Homozygosity for the CARD15 frameshift mutation 1007fs is predictive and frequent need for surgical intervention with high risk of re-stenosis. Am J Gastroenterol. (2009) 104:13780–5. doi: 10.1073/pnas.0706625104

67. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cézard JP, Belaiche J, et al. NOD2/CARD15 and other risk factors in a population-based case-control study of Crohn’s disease. J Clin Microbiol. (2006) 44:3166–71. doi: 10.1128/JCM.01967-14

68. Seiderer J, Schnitzler F, Brand S, Staudinger T, Pfennig S, Herrmann K, et al. NOD2/CARD15 and other risk factors in a population-based case-control study of Crohn’s disease. J Clin Microbiol. (2006) 44:3166–71. doi: 10.1128/JCM.01967-14

69. Samuelson DR, Charles TP, de La Rua NM, Taylor CM, Blanchard EE, Luo M, et al. Analysis of the lung microbiome in the “healthy” smoker and in COPD. PLoS ONE. (2011) 6:e16384. doi: 10.1371/journal.pone.0016384

70. Huang YJ, Sethi S, Murphy T, Nariay S, Boushey HA, Lynch SV. Airway microbiome dynamics in exacerbations of chronic obstructive pulmonary disease. J Clin Microbiol. (2014) 52:2813–23. doi: 10.1128/JCM.00335-14

71. Millares L, Ferrari R, Gallego M, Garcia-Nunez P, Perez-Brocal V, Espasa M, et al. Bronchial microbiome of severe COPD patients colonised by Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis. (2014) 33:1101–11. doi: 10.1007/s10096-013-2044-0

72. Wang Z, Bafadhel M, Haldar K, Spivak A, Mayhew D, Miller B, et al. Lung microbiome dynamics in COPD exacerbations. Eur Respir J. (2016) 47:1082–92. doi: 10.1183/13993003.01406-2015

73. Sun Z, Zhu QL, Shen Y, Yan T, Zhou X. Dynamic changes of gut and lung microorganisms during chronic obstructive pulmonary disease exacerbations. Kaohsiung J Med Sci. (2020) 36:107–13. doi: 10.1002/kjm2.12147

74. Bernascioni E, Pattarioni C, Koutsokera A, Pison C, Kessler R, Benden C, et al. Airway microbiota determines innate cell inflammatory or tissue remodeling profiles in lung transplantation. Am J Respir Crit Care Med. (2019) 194:1252–63. doi: 10.1164/ccrccm.201512-2424OC

75. Chen LW, Chen PH, Hsu CM. Commensal microbiota contribute to host defense against Escherichia coli pneumonia through toll-like receptors. Shock. (2011) 36:67–75. doi: 10.1097/SHK.0b013e3182184ae7

76. Schuit TJ, Lankelma JM, Scicluna BP, de Sousa e Melo F, Roelofs JJTH, de Boer JD, et al. The gut microbiota plays a protective role in the host defence against pneumococcal pneumonia. Gut. (2016) 65:575–83. doi: 10.1136/gutjnl-2015-309728

77. Sze MA, Tsuruta M, Yang SWJ, Oh Y, Man SFP, Hogg JC, et al. Changes in the intestinal microbiota in gut, blood, and lungs following acute LPS instillation into mice lungs (bacterial microbiota in gut, blood, and lungs after LPS. Infect Immun. (2014) 82:3281–32. doi: 10.1128/IAI.00073-14

78. Samuelson DR, Charles TP, de La Rua NM, Taylor CM, Blanchard EE, Luo M, et al. Analysis of the intestinal microbial community and inferred functional capabilities during the host response to Pneumocystis pneumonia. Exp Lung Res. (2016) 42:425–39. doi: 10.1080/10647934.2016.1258442

79. Gauget S, D’Ortona S, Ahnger-Pier K, Duan B, Surana NK, Lu R, et al. Intestinal microbiota of mice influences resistance to Staphylococcus aureus secondary infection. Infect Immun. (2015) 83:4003–14. doi: 10.1128/IAI.00037-15

80. Robert PD, Benjamin HS, Michael VN, Nicole RE, John RE-D, Theodore JS, et al. Enrichment of the lung microbiome with gut bacteria in sepsis and the acute respiratory distress syndrome. Nat Microbiol. (2016) 1:16113. doi: 10.1038/nmicrobiol.2016.113
Zuo L, Li Y, Lei P. Association of helicobacter pylori infection with chronic obstructive pulmonary disease and chronic bronchitis: a meta-analysis of 16 studies. *Infect. Dis. (2015) 47:597–603. doi: 10.3109/03636358.2014.989539*

Benjamin LJ, Hedin RHC, Koutoumpas CA, Ng ES, McCarthy IN, Prescott GN, et al. Smokers with active Crohn’s disease have a clinically relevant dysbiosis of the gastrointestinal microbiota. *Inflamm Bowel Dis. (2012) 18:1092–100. doi: 10.1007/s10069-011-1888-4*

Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connan JE. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. (Author Abstract). *Ann Intern Med. (2005) 142:233–9. doi: 10.13726/m003-4819-142-4.200502150-00005*

Office of the Surgeon General, Office on Smoking and Health (US). (2004). *Raising the Bar: A Report of the Surgeon General. Atlanta, GA: Centers for Disease Control and Prevention (US).*

Mahid SS, Minor KS, Soto RE, Hornung CA, Galandiuk S. Smoking and inflammatory bowel disease: a meta-analysis. *Mayo Clin Proc. (2006) 81:1462–71. doi: 10.4065/81.11.1462*

Sutherland L, Ramcharan S, Bryant H, Fick G. Effect of cigarette-smoking on recurrence of crohn’s disease. *Gastroenterology. (1990) 98:1123–8. doi: 10.1016/S0016-5085(90)90324-T*

Cosnes J, Carbonnel F, Carrat F, Beaugerie L, Cattan S, Gendre J. Effects of current and former cigarette smoking on the clinical course of Crohn’s disease. *Aliment Pharmacol Ther. (1999) 13:1403–11. doi: 10.1046/j.1365-2036.1999.00630.x*

Picco MF, Bayless TM. Tobacco consumption and disease duration in patients with inflammatory bowel disease are associated with fistulizing and strictureing behaviors in the first 8 years of Crohn’s disease. *Am J Gastroenterol. (2003) 98:363–8. doi: 10.1111/j.1527-0243.2003.02740.x*

Lindberg E, Järnerot G, Huitfeldt B. Smoking in Crohn’s disease: a systematic review and meta-analysis. *Inflamm Bowel Dis. (2014) 20:1496–501. doi: 10.1097/MIB.0000000000000129*

Ananthakrishnan AN, Khalili H, Konijeti GG, Higuchi LM, de Silva P, Korzenik JR, et al. A prospective study of long-term intake of dietary fiber in the faecal microbiota of monozygotic twins and their mothers. *Nature. (2010) 466:634–8. doi: 10.1038/nature09199*

Prager M, Böttner J, Gruner P, Ellinghaus D, Büning C. A promoter variant within the aryl hydrocarbon receptor gene is associated with an epithelial barrier defect in smokers with crohn’s disease. *Inflamm Bowel Dis. (2016) 22:2356–68. doi: 10.1097/MIB.0000000000000910*

Kim M, Gu B, Madison MC, Song HW, Norwood K, Hill AA, et al. Cigarette smoke induces intestinal inflammation via a Th17 cell-neutrophil axis. (report) (brief article). *Front Immunol. (2019) 10:75. doi: 10.3389/fimmu.2019.00075*

Breitbart M, Hewson I, Felts B, Mahaffy JM, Nulton J, Salamon P, et al. Metagenomic analyses of an uncultured viral community from human feces. *J Bacteriol (2003) 185:6202. doi: 10.1128/JB.185.20.6220-6223.2003*

Duerkop BA, Clements CV, Rollins D, Rodrigues JLM, and Hooper LV. A composite bacteriophage alters colonization by an intestinal commensal bacterium. *Proc Natl Acad Sci. (2012) 109:17621. doi: 10.1073/pnas.1206136109*

Reyes A, Haynes M, Hanson N, Angly FE, Heath AC, Rohwer F, et al. Viruses and gut virome: inter-individual variation and dynamic response to diet.(Report). *Genome Res. (2011) 21:1616–25. doi: 10.1101/gr.122705.111*

Norman, JM, Handley SA, Baldridge MT, Droit L, Liu CY, Keller BC, et al. Disease-specific alterations in the enteric virome in inflammatory bowel disease. *Cell. (2015) 160:447–60. doi: 10.1016/j.cell.2015.01.002*

Wagner J, Maksimovic J, Farries G, Sim WH, Bishop RE, Cameron DJ, et al. Bacteriophages in gut samples from pediatric crohn’s disease patients: metagenomic analysis using 454 pyrosequencing. *Inflamm Bowel Dis. (2013) 19:1598–608. doi: 10.1097/MIB.0b013e3182892477*

Main J, McKenzie H, Yeaman GR, Kerr MA, Robson D, Pennington CR, et al. Antibody to saccharomyces cerevisiae (bakers’ yeast) in Crohn’s disease. *BMJ. (1988) 297:1105–6. doi: 10.1136/bmj.297.6656.1105*

Sokol H, Leduq V, Aschard H, Pham-H P, Jegou S, Landman C, et al. Fungal microbiota dysbiosis in IBD. *Gut. (2017) 66:1039. doi: 10.1136/gutjnl-2015-310746*

Willner D, Purlan M, Haynes M, Schmieder R, Angly FE, Silva J, et al. Metagenomic analysis of respiratory tract DNA viral communities in cystic fibrosis and non-cystic fibrosis individuals. *PLOS ONE. (2009) 4:e7370. doi: 10.1371/journal.pone.0007370*

Young JC, Chehoud C, Bittering K, Bailey A, Diamond JM, Cantu E, et al. Viral metagenomics reveal blooms of alelloviruses in the respiratory tract of lung transplant recipients. *Am J Transplant. (2015) 15:200–209. doi: 10.1111/ajt.13031*

McManus TE, Marley AM, Baxter N, Christie SN, Elborn JS, Nell HJ, et al. High levels of Epstein-Barr virus in COPD. *Eur Respir J. (2008) 31:1221. doi: 10.1183/09031916.0010705*

Utokaparch S, Sze MA, Gosselin JF, McDonough JE, Elliott WM, Hogg JC, et al. Respiratory Viral Detection and Small Airway Inflammation in Lung Tissue of Patients with Stable, Mild COPD. *COPD. (2014) 11:197–203. doi: 10.3109/15412555.2013.836166*

Tan DBA, Amran FS, Teo T-H, Price P, and Moodley YP. Levels of CMV-reactive antibodies correlate with the induction of CD28null T cells and systemic inflammation in chronic obstructive pulmonary disease (COPD). *Cell Mol Immunol. (2016) 13:551–3. doi: 10.1038/cmi.2015.4*

Charlson ES, Diamond JM, Bittering K, Fitzgerald AS, Yadav A, Haas AR, et al. Lung-enriched organisms and aberrant bacterial and fungal respiratory microbiota after lung transplant. Am J Respir Crit Care Med. (2012) 186:536–45. doi: 10.1164/rccm.201204-0693OC*

Martinsen EMH, Eagan TML, Leiten EO, Haaland I, Husebo GR, Sanseverino W, et al. A study of the airway mycobiome in COPD patients and controls. *Eur Respir J. (2019) 54:OA1601. doi: 10.1183/13993003.congress-2019.OA1601*

Su J, Liu H-Y, Tan X-I, Ji Y, Jiang Y-X, Prabhakar M, et al. Sputum bacterial and fungal dynamics during exacerbations of severe COPD. *PLOS ONE. (2015) 10:e0130736. doi: 10.1371/journal.pone.0130736*

Ananthakrishnan A. Epidemiology and risk factors for IBD. *Nat Rev Gastroenterol Hepatol. (2015) 12:205–17. doi: 10.1038/nrgastro.2015.34*

Ananthakrishnan AN, Khalili H, Konijeti GG, Higuchi LM, de Silva P, Korzenik JR, et al. A prospective study of long-term intake of dietary fiber...
and risk of crohn’s disease and ulcerative colitis. Gastroenterology. (2013) 145:970–7. doi: 10.1053/j.gastro.2013.07.050

129. Roberts CL, Keita ÁV, Duncan SH, O’Kennedy N, Söderholm JD, Rhodes JM, et al. Translocation of Crohn’s disease Escherichia coli across M-cells: contrasting effects of soluble plant fibres and emulsifiers. Gut. (2010) 59:1331–9. doi: 10.1136/gut.2009.195370

130. Rodríguez-Cabezas ME, Gálvez J, Lorente MD, Concha A, Camuesco D, Azzouz S, et al. Dietary fiber down-regulates colonic tumor necrosis factor α and nitric oxide production in trinitrobenzenesulfonic acid-induced colitic rats. J Nutr. (2002) 132:3263–71. doi: 10.1093/jn/132.11.3263

131. Rodriguez-Cabezas ME, Gálvez J, Camuesco D, Lorente MD, Concha A, Martinez-Augustin O, et al. Intestinal anti-inflammatory activity of dietary fiber (Plantago ovata seeds) in HLA-B27 transgenic rats. Clin Nutr. (2003) 22:463–71. doi: 10.1016/S0261-5614(03)00045-1

132. Kovarik JJ, Tillingwer W, Hofer J, Holst MA, Heinitz H, Saemmann MD, et al. Impaired anti-inflammatory efficacy of β-glucan in patients with IBD. Eur J Clin Invest. (2011) 41:291–8. doi: 10.1111/j.1365-2263.2010.02407.x

133. Breuer RL, Soergel KH, Lashner BA, Christ ML, Hanauer SB, Vanagas A, et al. Short chain fatty acid rectal irrigation for left-sided ulcerative colitis: a randomised, placebo controlled trial. Gut. (1997) 40:485–91. doi: 10.1136/gut.40.4.485

134. Thibault R, De Coppent P, Daly K, Bourrelle A, Cuff M, Bonnet C, et al. Down-regulation of the monocarboxylic transporter 1 is involved in butyrate deficiency during intestinal inflammation. Gastroenterology. (2007) 133:1916–27. doi: 10.1053/j.gast.2007.08.041

135. Howe H, Mortensen P. Influence of intestinal inflammation (IBD) and small and large bowel length on fecal short-chain fatty acids and lactate. Dig Dis Sci. (1995) 40:1372–80. doi: 10.1007/BF02065554

136. De Preter V, Machiels K, Joossens M, Arijs I, Matthys C, Veermeire S, et al. Faecal metabolite profiling identifies medium-chain fatty acids as discriminating compounds in IBD. Gut. (2015) 64:447–58. doi: 10.1136/gutjnl-2013-306423

137. Joossens M, De Preter V, Ballet V, Verbeke K, Rutgeerts P, Vermeire S. Association between diet and chronic obstructive pulmonary disease: independent beneficial effects of fruits, whole grains, and alcohol in subjects selected from general practice. Eur Resp J. (2002) 20:3138–9. doi: 10.1183/09031936.02.0056402

138. Unger MM, Spiegel J, Dillmann K-U, Grundmann D, Linker R, Kleinewietfeld M. Role of gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. Nat Med. (2014) 20:159–66. doi: 10.1038/nm.3444

139. Mariño E, Richards J, McLeod K, Stanley D, Yap Y, Knight J, et al. Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. Nat Med. (2014) 20:159–66. doi: 10.1038/nm.3444

140. Watson L, Margetts B, Howarth P, Dorward M, Thompson R, Little P. The association between diet and chronic obstructive pulmonary disease in subjects selected from general practice. Eur Resp J. (2002) 20:3138–9. doi: 10.1183/09031936.02.0056402

141. Butler L, Koh WP, Lee H, Yu MC, London SJ. Dietary fiber and reduced cough with phlegm - a cohort study in Singapore. Am J Respir Crit Care Med. (2004) 170:279–87. doi: 10.1164/rccm.200306-789OC

142. Colik F, Topcu F. Nutritional risk factors for the development of chronic obstructive pulmonary disease (COPD) in male smokers. Clin Nutr. (2006) 25:955–61. doi: 10.1016/j.clnu.2006.04.006

143. Trompette A, Gollwitzer ES, Yadava K, Sichelstiel AK, Sprenger N, Ngomsbru C, et al. Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. Nat Med. (2014) 20:159–66. doi: 10.1038/nm.3444

144. Nath K, Burel J, Shankar V, Pritchard A, Towers M, Looke D, et al. Clinical factors associated with the humoral immune response to influenza vaccination in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. (2013) 9:51–6. doi: 10.2147/COPD.S53590

145. Parpaleix A, Boyer L, Wiedemann A, Lacabartaz C, Margarit L, Enouf V, et al. Impaired humoral and cellular immune responses to influenza vaccination in chronic obstructive pulmonary disease patients. J Allergy Clin Immunol. (2017) 140:1754–71756. doi: 10.1016/j.jaci.2017.07.038

146. Chapman-Kiddell CA, Davies PSW, Gillen L, Radford-Smith GL. Role of diet in the development of inflammatory bowel disease. Inflamm Bowel Dis. (2010) 16:137–51. doi: 10.1002/ibd.20968

147. Manzel A, Muller D, Hafer D, Erdmann Y, Linker P, Kleinewietfeld M. Role of “western diet” in inflammatory autoimmune diseases. Curr Allergy Asthma Rep. (2014) 14:404. doi: 10.1007/s11882-013-0404-6

148. Nappo F, Esposito K, Ciolfi M, Guagliano G, Molinari AM, Paolissio G, et al. Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients: role of fat and carbohydrate meals. J Am Coll Cardiol. (2002) 39:1145–50. doi: 10.1016/S0735-1097(02)01741-2

149. Wu G, Chen J, Hoffmann C, Bittinger K, Ying-Yu C, Keilbaugh S, et al. Linking long-term dietary patterns with gut microbial enterotypes. Science. (2011) 334:105–8. doi: 10.1126/science.1208344

150. Pendyala S, Walker JM, Holt PR. A high-fat diet is associated with endotoxemia that originates from the gut. Gastroenterology. (2012) 142:1100–01.e1102. doi: 10.1053/j.gastro.2012.01.034

151. van Oostrom A, Sijmonsma TP, Verseden C, Jansen E, de Koninck M, Fiers W, et al. Postprandial recruitment of neutrophils may contribute to endothelial dysfunction. J Lipid Res. (2003) 44:576–83. doi: 10.1194/jlr.M200419-JLR200

152. Tunnacliffe PA, Bajchek P, Fulton L, Gordon JD. Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell Host Microbe. (2008) 3:213–23. doi: 10.1016/j.chom.2008.02.015

153. Martinez-Medina M, Denizot J, Droux N, Robin F, Billard E, Bonnet R, et al. Western diet induces dysbiosis with increased E. coli in CEACAM1 mice, alters host barrier function favouring AEC colonisation. Gut. (2014) 63:116–24. doi: 10.1136/gutjnl-2012-304119

154. Hassan V, Hassan S, Seyed-Javad P, Ahmad K, Asieh H, Maryam S, et al. Association between dietary fiber intake and inflammation in inflammatory bowel disease (IBD) activity. Med J Malaysia. 68:34–8. doi: 10.1371/journal.pone.0132036

155. Wu S, Zang YG, Lu R, Xia Y, Zhou D, Petroz EO, et al. Intestinal epithelial vitamin D receptor deletion leads to defective autophagy in colitis. Gut. (2015) 64:1082–94. doi: 10.1136/gutjnl-2014-307436

156. Ooi JH, Li Y, Rogers CJ, Cantonra MT. Vitamin D regulates the gut microbiome and protects mice from dextran sodium sulfate-induced colitis. J Nutr. (2013) 143:1679–86. doi: 10.3945/jrn.113.180794

157. Jin D, Wu S, Zhang YG, Wu L, Xia Y, Dang Z, Petroz EO, et al. Intestinal epithelial vitamin D receptor causes dysbiosis and changes the functions of the murine intestinal microbiome. Clin Ther. (2015) 37:996–1009.e1007. doi: 10.1016/j.clinthera.2015.04.004
183. Arnold GL, Herlemann DP, Klintzke P, Berlin P, Kreikemeyer B, Iaster R, et al. Vitamin D administration leads to a shift of the intestinal bacterial composition in Crohn’s disease patients, but not in healthy controls. J Dig Dis. (2018) 19:225–34. doi: 10.1111/1751-2980.12591

182. Townsend CM, Parker CE, Macdonald J, Nguyen TM, Jairath V, Rutgeerts P, Hiele M, Geboes K, Peeters M, Penninckx F, Aerts R, et al. Steinhart AH, Feagan BG, Wong CJ, Vandervoort M, Mikolainis S, Croitoru J, et al. Circulating 25-hydroxyvitamin D, nasopharyngeal microbiota, and bronchiolitis severity. Pediatr Allergy Immunol. (2018) 29:877–80. doi: 10.1111/pai.12977

180. Liu P, Stenger S, Li H, Wenzel L, Tan B, Krutzik S, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. (2006) 311:1770–3. doi: 10.1126/science.1123933

181. Jernberg C, Löfmark S, Edlund C, Jansson J. Long-term ecological impacts of antibiotic administration on the human intestinal microbiota. PLoS Biol. (2010) 8:e1000445. doi: 10.1371/journal.pbio.1000445

179. Palmer C, Bik EM, DiGiulio DB, Relman DA, Brown PO. Development of anti-bacterial treatment for chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev. (2010) CD009764.pub3 doi: 10.1002/14651858.CD009764.pub3

177. Janssens W, Bouillon R, Claes B, Carremans C, Lehouck A, Buysschaert I, et al. Vitamin D deficiency is highly prevalent in COPD and correlates with variants in the vitamin D-binding gene. J Clin Endocrinol Metab. (2007) 92:3796–802. doi: 10.1210/jc.2007-0328

176. Hille R, Wüthrich B, Willimsky G, Busto U, Dörfler R, Belch JJF, et al. Pulmonary function in chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev. (2010) CD001863. doi: 10.1002/14651858.CD001863.pub5

175. Bhattacharya S, Lill SA, Currie D, Jones PS, Glaudemans AWJ, van der Wal AC, et al. Meta-analysis of randomized controlled trials of faecal microbiota transplantation for chronic obstructive pulmonary disease (COPD). Aliment Pharmacol Ther. (2014) 39:1118–29. doi: 10.1111/apt.12935

174. Shaw YS, Blanchard FJ, Bernstein NC. Association between the use of antibiotics for chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev. (2010) CD009764.pub3 doi: 10.1002/14651858.CD009764.pub3

173. Hille R, Wuthrich B, Willimsky G, Busto U, Dörfler R, Belch JJF, et al. Pulmonary function in chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev. (2010) CD001863. doi: 10.1002/14651858.CD001863.pub5

172. Kanhere RM, He AJ, Chassaing AB, Ziegler TT, Alvarez TJ, Ivie TE, et al. Bolus weekly vitamin D3 supplementation impacts gut and airway microbiota with variants in the vitamin D-binding gene. J Crohn's Colitis. (2012) 10:CD009764.pub3 doi: 10.1002/14651858.CD009764.pub3

171. Balcells ME, Yokobori N, Hong B-Y, Corbett J, Cervantes J. The lung microbiota of the infant intestine. Gut. (2015) 64:585–92. doi: 10.1136/gutjnl-2014-308923

170. Herath SC, Normansell R, Maisey S, Poole P. Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev. (2010) CD009764.pub3 doi: 10.1002/14651858.CD009764.pub3

169. Shahinas D, Silverman M, Sittler T, Chiu C, Kim P, Allen-Vercoe E, et al. Toward an understanding of changes in diversity associated with fecal microbiome transplantation based on 16S rRNA gene deep sequencing. MBio. (2012) 3:e00338-12. doi: 10.1128/mBio.00338-12

168. Rossen NG, Fuentes S, van Der Spek MJ, Tijssen JG, Hartman JHA, Duflou JMK, et al. Faecal microbiota transplantation for inflammatory bowel disease: a systematic review and meta-analysis. NPJ Prim Care Respir Med. (2015) 25:15002. doi: 10.1038/npjpcrm.2015.2

167. Widdel F, Kroppenstedt RM, Lesnefsky EJ, Erb K, Stackebrandt E. Evolutionary recruits shared by a range of bacterial phyla. Proc Natl Acad Sci U S A. (2001) 98:12139–44. doi: 10.1073/pnas.211214398

166. Raftery et al. Links Between IBD and COPD

Inflamm Bowel Dis

Cochrane Database Syst Rev.
doi: 10.1002/0016-5085(95)90121-3

doi: 10.1053/gast.2002.34225

doi: 10.1007/s10620-007-9760-1

doi: 10.1093/tptr/503.9.85

doi: 10.1111/j.1365-2036.2012.05033.x

Conflict of Interest: The Authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Raftery, Tsantikos, Harris and Hibbs. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.